Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) Director Robert Alexander Ingram sold 12,500 shares of Edwards Lifesciences Corp stock in a transaction dated Thursday, July 31st. The stock was sold at an average price of $90.26, for a total transaction of $1,128,250.00. Following the completion of the sale, the director now directly owns 30,541 shares of the company’s stock, valued at approximately $2,756,631. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 1.91% during mid-day trading on Friday, hitting $91.97. 1,899,876 shares of the company’s stock traded hands. Edwards Lifesciences Corp has a 1-year low of $60.62 and a 1-year high of $94.50. The stock’s 50-day moving average is $85.98 and its 200-day moving average is $77.78. The company has a market cap of $9.712 billion and a P/E ratio of 13.02.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp will post $3.28 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $90.00.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.